02680nas a2200229 4500008004100000245013800041210006900179260001400248300001200262490000700274520188600281653001702167653002502184653002402209653002202233653002802255653002802283653002902311100002602340700002202366856006202388 2025 eng d00aPhytochemical-Infused Chitosan Biocomposites: Cytotoxic, Antidiabetic, and Anticoagulant Potential of Vaccinium and Zingiber Extracts0 aPhytochemicalInfused Chitosan Biocomposites Cytotoxic Antidiabet cJune 2025 a983-9880 v173 a

Background: The integration of plant-derived bioactives with natural polymers offers a sustainable approach to therapeutic biomaterials. Vaccinium sect. Cyanococcus (blueberry) and Zingiber officinale (ginger) are known for their antidiabetic and anticoagulant properties, while chitosan serves as a biodegradable, biocompatible carrier. Aim: To develop a chitosan-based biocomposite loaded with V. cyanococcus and Z. officinale extracts and evaluate its in vitro antidiabetic, anticoagulant, and cytotoxic activities. Materials and Methods: Biocomposites were prepared by incorporating aqueous extracts of V. cyanococcus and Z. officinale into a chitosan matrix. Antidiabetic activity was assessed via α-amylase and α-glucosidase inhibition assays. Anticoagulant activity was evaluated using clotting time analysis. Biocompatibility was tested via the brine shrimp lethality assay. Data were analyzed statistically, with significance set at p<0.05. Results: The biocomposite showed significant, dose-dependent inhibition of α-amylase (48.03-85.09%) and α-glucosidase (47.03-84.04%) activities, comparable to the standard drug acarbose (p>0.05). Clotting time in the treated group (8.40±0.10 min) showed a mild, non-significant decrease compared to control (8.60±0.10 min). Cytotoxicity was minimal at lower concentrations, with nauplii viability remaining above 60% even at the highest dose after 48 hr. Conclusion: The chitosan-based biocomposite enriched with V. cyanococcus and Z. officinale exhibits promising antidiabetic and mild anticoagulant activity with acceptable biocompatibility. These findings support its potential use in managing metabolic and thrombotic conditions.

10aBiocomposite10aEnzymatic inhibition10aGlycemic modulation10aHerbal bioactives10aNatural polysaccharides10aPlant-derived compounds10aTherapeutic biomaterials1 aVelraj, Maria, Sharon1 aRajasekar, Arvina uhttps://phcogres.com/article/2025/17/3/105530pres20252284